107229-64-1Relevant articles and documents
Spiro compounds, preparation method thereof, intermediate, pharmaceutical composition and application
-
Paragraph 0142; 0147; 0148, (2018/04/02)
The invention discloses a spiro compound as shown in a formula I, a pharmaceutically acceptable salt, a hydrate, a solvate, an optical isomer or a prodrug of the spiro compound, as well as a preparation method, an intermediate, a pharmaceutical composition and an application of the spiro compound. The spiro compound disclosed by the invention has the activity of serving as protein kinase inhibitors and tyrosine kinase inhibitors such as c-Met, and the spiro compound can be used for treating diseases caused by the abnormal activity of kinases, such as cancer, or used for preparing medicaments for treating the diseases.
3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS
-
Page/Page column 66, (2010/11/30)
Compounds of the formula (I), wherein: -X=Y- is selected from -CR2=CR3- and -CR2=N-; R1 is selected from H, halo, NRR', NHC(=O)R, NHC(=O)NRR', NH2SO2R, and C(=O)NRR'; R2 and R3 (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R4 is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R5 is selected from R5’, halo, NHR5’, C(=O)NHR5’, OR5’, SR5’, NHC(=O)R5’, NHC(=O)NHR5’, NHS(=O)R5’, wherein R5’ is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework
Abe, Yoshito,Kayakiri, Hiroshi,Satoh, Shigeki,Inoue, Takayuki,Sawada, Yuki,Imai, Keisuke,Inamura, Noriaki,Asano, Masayuki,Hatori, Chie,Katayama, Akira,Oku, Teruo,Tanaka, Hirokazu
, p. 564 - 578 (2007/10/03)
A novel class of potent, selective, and orally active non-peptide bradykinin (BK) B2 receptor antagonists were designed and synthesized starting from 8-benzyloxyimidazo[1,2-α]pyridine derivative 2. The unique screening lead (2) was discovered b